VIVALIS SA

VIVALIS (Euronext: VLS) develops innovative technologies for manufacture of products in avian and mammalian-based cell lines. The company’s EB66® cell line is widely used in the research and development of vaccines for human and animal health and for antibody-based therapeutics where the enhancement of ADCC is a desired mechanism of action. The company also offers process development and GMP manufacturing services for eukaryotic based products (viruses and antibodies/proteins) from preclinical through Phase II levels of production.